 | Gail Schulze
CEO and Executive Chair of the Board Ms. Schulze joined Zosano in May 2008. She is also a Board member of Cerus since October 2007. Gail was CEO of YM Biosciences US and President, YM Biosciences, Inc., a global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was President, CEO and Director of Eximias Pharmaceutical Corporation. From 2001 to 2004, Ms. Schulze was COO and deputy CEO of Aventis Behring LLC, a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, was Senior Executive Vice President and Chief Commercial Officer. From 1996 to 1997 she was corporate Vice President of Allegiance Healthcare Corporation and from 1979 to 1996 Ms. Schulze held multiple positions within Baxter Healthcare Corporation, most recently as President of the US Managed Care division and President of Renal Division Europe. | | | |  | Thorsten von Stein, MD, PhD
Chief Medical Officer Dr. von Stein joined Zosano from Tercica where he served as Senior Vice President and Chief Medical Officer from 2005 to 2009. From 2001 to 2005, he served as Chief Medical Officer and previously Vice President of Clinical Development at NeurogesX. From 1994 to 2001, Dr. von Stein held positions of increasing responsibility in clinical development and project management at Roche Palo Alto and F. Hoffmann-La Roche AG in Basel, Switzerland. Dr. von Stein received his medical degree from Munich University, Germany, and his Ph.D. in Computer Science from the University of Hamburg, Germany. | | | |  | John M. Vuko
Executive Vice President and Chief Financial Officer
John Vuko joined Zosano Pharma in June 2008 and is the company’s Chief Financial Officer and Executive Vice President. Mr. Vuko is responsible for the financial, legal, human resource and information technology matters of the company. Prior to joining Zosano, Mr. Vuko was the Chief Financial Officer at Genitope Corporation that was developing a personalized immunotherapy and monoclonal antibody to treat follicular non-Hodgkin’s lymphoma. While Mr. Vuko was at Genitope, they raised over $200 million in the public markets. Before joining Genitope, Mr. Vuko was the Executive Vice President and Chief Financial Officer for Incyte Corporation which provided genomic information and services to the research community. While at Incyte, Mr. Vuko assisted in raising over $600 million in the public markets. Prior to Genitope, Mr. Vuko held similar positions at Ross Stores Inc., Achievement Radio Holdings and CooperVision Inc. and CooperLasersonics Inc. Mr. Vuko began his professional career at Price Waterhouse & Co. and is a CPA. | | | | 
| Peter Daddona, PhD
Chief Scientific Officer
Peter Daddona has over 30 years of pharmaceutical research and development experience. Prior to establishing this new independent company, he served as Vice President, Scientific Leader of The Macroflux® Internal Venture, one of Johnson & Johnson’s first Internal Ventures. Previously he was Vice President of Macroflux® Technology Development and Biological Sciences at ALZA Corporation in Mountain View Ca. and held an appointment as Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, he served as Vice President, Immunobiology Research at Centocor, in Malvern Pa., where he focused on preclinical development of therapeutic monoclonal antibodies. Most notably he is a co inventor on the original Remicade patents. Prior to joining Centocor, he served as Associate Professor of Biological Chemistry and Internal Medicine at the University of Michigan. Dr Daddona earned his Ph.D. from the University of Connecticut and post-doctoral training at Duke University. | | | |  | Greg Yedinak
Vice President, Manufacturing Operations Prior to joining Zosano Pharma, Greg served most recently as Vice President, Process Sciences and Manufacturing at Nuvelo. In that role, he was responsible for the in-house and outsourcing operations for Nuvelo’s clinical pipeline. Prior to that he was at Amgen (formerly Abgenix) where he was Vice President, Manufacturing, Facilities and Engineering. In that position, he was responsible for directing the clinical and commercial manufacturing facilities and engineering operations at sites in Fremont, California and Vancouver, British Columbia, and played a pivotal role in managing the Chemistry Manufacturing and Controls section of multiple U.S. and global regulatory submissions, including the Biologics License Application for Abgenix's lead product candidate, panitumumab. Previously, he spent 15 years at Genentech, where he had various roles in the manufacturing of more than 20 marketed products and product candidates. He received a BS in Biological Sciences from the University of California-Irvine. | | | | 
| Kim Gaumer
Vice President, Regulatory Affairs and Quality Assurance
Kim Gaumer is Vice President of Regulatory Affairs and Quality Assurance and joined the company in February of 2007. Kim has over 20 years experience in pharmaceutical drug development, including seven years in nonclinical toxicology research and 14 years in regulatory affairs. Her experience includes oral, transdermal and implanted drug delivery systems, with an emphasis on drug device combinations including novel drug delivery systems. She has extensive experience with CNS drug products and analgesics, including Duragesic transdermal chronic pain fentanyl patch, cardiovascular drug Covera HS, Concerta for ADHD, and IONSYS , a non-invasive patient-controlled analgesic combination product that was recently approved in the US and across the European Union. Her regulatory experience covers pre-Phase 1 through post-marketing support, including experience with controlled drugs and development of risk management programs. | | | |
| Daniel Hunt
Vice President, Business Development Dan Hunt has 20 years of business development, transactional, alliance management, finance, operational, legal and IP experience with prominent life science companies, including Genentech, Abgenix, Roche and Chiron.
During his career he has acquired extensive experience integrating science, business legal disciplines in connection with life science transactions. Mr Hunt has led and closed hundreds of transactions with cumulative valuations in excess of $1B. Prior to joining Zosano Pharma, Mr. Hunt was Associate General Counsel, Licensing, Contracts Management and Patent Law at Genentech, where he was responsible for managing Genentech’s business development and transactional activities in collaboration with Genentech’s business development, finance, research and alliance management groups. Prior to Genentech, Mr. Hunt was the Director of Legal Affairs at Abgenix, where he was responsible for all company transactions, ranging from acquisitions and strategic collaborations to ordinary course transactions, and engaged in strategic planning for business development, product development, acquisition and manufacturing activities. At Roche Molecular Systems, Mr. Hunt was Chief Corporate Counsel. He was responsible for business development and transactional support and managed Roche’s PCR licensing program. Prior to Roche, Mr. Hunt was Senior Corporate Counsel at Chiron.
Mr. Hunt began his career as a patent litigator and securities attorney at the law firm of Morrison & Foerster. Mr. Hunt obtained his law degree from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of Colorado, Boulder. | | | | | | |
|
